COVID-19 Real-Time Learning Network

Our updated page summarizes the current pause in U.S. administration of the Johnson & Johnson/Janssen COVID-19 vaccine and provides relevant clinical guidance and resources.

Revised FDA regulations seek to facilitate serial testing programs that pool specimens from asymptomatic individuals.

Experts including leaders from CDC discuss the current Johnson & Johnson/Janssen COVID-19 vaccine situation and anticipated next steps in this recorded webinar.

FDA announcement revoking its EUA for bamlanivimab when administered alone.

CDC information for the public about vaccine breakthrough cases.

FAQs on diagnosis and treatment of vaccine-induced thrombosis, a rare but serious adverse event that has been observed in 6 U.S. patients to date.